Search

The article presents the views of several experts on the use of adjuvant chemotherapy for stage II colon cancer. According to professor Leonard B. Saltz, patients with stage II colon cancer are among the most complicated initial consultations. Assistant professor Cathy Eng says that for stage II colon cancer, there is no definitive recommendation regarding initiation of adjuvant chemotherapy.

The article discusses the findings of various studies on adjuvant endocrine therapy in premenopausal women diagnosed with breast cancer. One study found that the therapeutic benefit of tamoxifen therapy may not be limited to 5 years. A study which evaluated the effect of tamoxifen and steroidal aromatase inhibitor exemestane on endometrial status discovered that exemestane increased endometrial thickness and uterine volume. Another study found that anastrozole is more effective than tamoxifen.

The article discusses the use of adjuvant chemotherapy for breast cancer. A study discovered that the absence of screening and adjuvant treatment increased the rates of mortality in patients with breast cancer. Although questions about the effectiveness of adjuvant therapy, various studies have reported positive results on its impact on survival rates. The article highlights the findings of studies concerning adjuvant therapy.

The authors reflects on the clinical efficacy of adjuvant chemotherapy for colon cancer.

The article discusses the common side effects suffered by patients undergoing chemotherapy. A study which found that adjuvant chemotherapy in women with breast cancer can be associated with memory deterioration is cited. Research suggests that the carriers of apolipoprotein E (APOE) gene's E4 allele may have a higher risk of developing long-term cognitive defects after receiving chemotherapy. It also mentions studies indicating the role of neural damage in cognitive impairment.

The article presents the findings research related to the treatment and management of cancer. A prospective study indicates the effectiveness of contemporary mammography screening in reducing breast cancer mortality. A placebo-controlled trial shows that sorafenib significantly improved progression-free survival in patients with thyroid cancer. Another study reveals that ovarian suppression with adjuvant exemestane reduces the risk of premenopausal breast cancer recurrence in women.

This article discusses research being done on the pathological response rates of neoadjuvant radiation and chemotherapy in patients with breast cancer, referencing a study by S. Adams et al, published in the journal "Breast Cancer Research and Treatment" in 2010.

The article focuses on a study which examined the influence of neoadjuvant chemotherapy on the overall survival (OS) and disease-free survival (DFS) of patients with breast cancer.

The article focuses on a study which found that adjuvant chemotherapy with paclitaxel, gemcitabine and cisplatin improved overall survival (OS) and disease-free survival (DFS) for patients with high-risk invasive bladder cancer.

This section offers news briefs concerning oncology, including the effectiveness of adjuvant chemotherapy with paclitaxel, gemcitabine and cisplatin for treating invasive bladder cancer, and the efficacy of adjuvant chemoradiation plus interferon alfa-2b for treating resected pancreatic adenocarcinoma.

The article focuses on a German GeparQuattro study, which showed that the addition of trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy would yield a high rate of pathologic complete response in patients with HER-2-positive breast cancer.

The article discusses a study by J. Ji and colleagues on the role of miR-26, a microRNA, in determining survival and response to adjuvant therapy among individuals with hepatocellular carcinoma published in the journal "New England Journal of Medicine."

The article discusses research which compared the efficacy of adjuvant therapy with exemestane against tamoxifen in reducing breast cancer recurrence in high-risk patients in the Netherlands, presented by lead researcher Cornelis van de Velde, at the joint 15th European CanCer Organization and 34th European Society for Medical Oncology Multidisciplinary Congress in Berlin, Germany from September 20 to 24, 2009.

The article focuses on the biochemical beta-glucans. They are naturally-occuring polysaccharides from food sources such as whole wheat, barley, and mushrooms. Health benefits featured include reducing symptoms of upper respiratory tract infections (URI), being an immunologic adjuvant for certain cancers, and improvement of bone marrow activity.

The article reports on the findings of the ESPAC-3 trial conducted by John P. Neoptolemos and colleagues which concluded that there was no survival difference between adjuvant treatment of pancreatic ductal adeoncarcinoma and the U.S. standard gemcitabine, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Orlando, Florida from May 29 to June 2, 2009.

The article discusses research on the effect of adjuvant therapy with pegylated interferon alfa-2b on patients with resected stage II melanoma, that references a study by John Glaspy and colleagues published in a 2009 issue of the "Journal of Clinical Oncology."

The article discusses a study, published in a 2009 issue of "Journal of Clinical Oncology," which examined the benefit of adjuvant chemotherapy to patients with colon cancer.

The article reports on the results of a study which analyzed a prospective database of clinical and pathological information for patients treated for renal cell carcinoma between 1989 and 2005. The study found that patients at high risk for recurrent renal cell carcinoma may require adjuvant therapy rather than surgery alone to improve outcome. Researchers reported that complete response occurred in 7% of patients with metastatic disease who received immunotherapy.

The article focuses on a study which suggested that adjuvant chemotherapy should not be considered the standard of care in stage Ib non-small cell lung cancer. In this study, researchers randomly assigned patients to adjuvant chemotherapy or observation four to eight weeks following tumor resection. Chemotherapy consisted of intravenous (IV) paclitaxel and carboplatin.

The article reports on the updated results from the European Cooperative Trial in Operable Breast Cancer. The results showed that patients assigned to primary systemic therapy have more frequently underwent breast conserving surgery compared with those assigned to adjuvant chemotherapy and did so without increased local tumor recurrence. The results were presented by Wolfgang Eiermann, medical director at Red Cross Women's Hospital in Munich, Germany, at the 2008 Breast Cancer Symposium.

The article discusses research on the increased risk for late recurrence in breast cancer patients after five years of adjuvant therapy. It references a study published in a 2008 issue of the "Journal of National Cancer Institute." The trial which included 2,838 patients with stage I-III breast cancer treated with adjuvant and neoadjuvant systemic therapy was conducted between January 1, 1985 and November 1, 2001. Findings showed that for those with stage I disease, there was 7% increased risk, and 11% increased risk for those with stage II disease.

The article reports on a study which found that adjuvant pegylated interferon alfa-2b improved the recurrence-free survival in patients with stage III melanoma. Researchers for the European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group stratified the previously grouped participants for microscopic versus macroscopic nodal involvement, number of positive nodes, ulceration and tumor thickness, sex and study center.

The article focuses on a study which investigated the effect of cisplatin plus gemcitabine on patients diagnosed with muscle-invasive bladder carcinoma. The study, which was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held from May 30 to June 3, 2008, randomly assigned patients to either standard chemotherapy at relapse or adjuvant chemotherapy with cisplatin and gemcitabine. It concluded that cisplatin and gemcitabine did not improve survival in the patients.

The article presents a case study of a 50-year-old premenopausal woman who came to an oncologist for the recommendations of adjuvant therapy after lumpectomy. An ultrasound confirmed the presence of a 1.2cm mass at the upper outer quadrant of the patient's right breast. She had menarche at age 13 and has never been pregnant.

The article discusses a study of patient preferences for surgical and adjuvant treatment options for rectal cancer, which was published in the "Archives of Surgery." Results showed that the strongest preference was to avoid abdominoperineal resection. In addition, 65% were willing to trade a mean of 34% of their life expectancy to avoid the treatment and the resulting stoma. Meanwhile, 91% of surgeons were willing to trade 25% of patients' life expectancies to avoid the treatment.

The article discusses a study on the use of lapatinib in tumorigenic breast cancer stem cells in women receiving neoadjuvant treatment, which was presented at the 6th European Breast Cancer Conference in Berlin, Germany in April 2008. Tumor regression was observed after six weeks of lapatinib treatment. According to instructor Angel A. Rodriguez, small subpopulations of cells with tumorigenic potential are resistant to conventional chemotherapy.

The article discusses a study on the use of adjuvant therapy for stage II colon cancer, which was presented at the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Symposium in April 2008. According to Paul F. Engstrom, for stage II colorectal cancer patients, available data weigh against opting for adjuvant therapy. He added that the weight of evidence in the medical literature favors not treating the patients.

The article discusses the use of adjuvant chemotherapy in patients with stage II colon cancer. According to a trial, FOLFOX chemotherapy provides an advantage with respect to disease-free survival in patients who have stage II disease. Meanwhile, one of the authors says that thousands of patients must be included to prove that a therapy improves survival from 80% to 82%. It stresses that all stage II cancers are not created equal.

The article discusses the benefit of extended adjuvant endocrine therapy among women with breast cancer after five years of tamoxifen. The author states that breast cancer-related deaths occur after completion of tamoxifen therapy, however, studies found that extended therapy after completion of tamoxifen can reduce the recurrence rates. Letrazole, (Femara, Novartis) a nonsteroidal aromatase inhibitor treatment helps reduce the risk by 42% and metastases by 40%.

The article discusses two studies concerning the prediction of risk of recurrence of estrogen-receptor (ER) positive breast cancer following adjuvant therapies. A study which examined tumor specimens in 430 patients found that tamoxifen plus chemotherapy showed decreased risk of recurrence. Another study discovered that Oncotype DX 21-gene RS assay is a significant predictor of recurrence.

The article discusses research on the effect of chemotherapy on the recurrence of uterine papillary serous carcinoma. It references a study of 163 patients, diagnosed between 1993 and 2006, and divided into groups that where given either observation, radiation, or chemotherapy with or without radiation. Findings showed that adjuvant chemotherapy benefited patients with surgical stage I or II uterine papillary serous carcinoma with low risk of recurrence.

The article discusses a research on a combination regimen of clarithromycin, lenalidomide and dexamethasone (BiRD) as a first-line therapy for multiple myeloma. It references a study by R. Niesvizky et al, published in a 2008 issue of "Blood." The regimen being found to be effective and well tolerated is reported.

The article provides two opposing answers to a question of whether targeted molecular agents should be used as neoadjuvant therapy for metastatic renal cell carcinoma.

This article reports that the present standards for HER2 protein determination may not be ideal for choosing which breast cancer patients receive adjuvant trastuzumab. The results from the National Surgical Adjuvant Breast and Bowel Project B-31 clinical trial, which examined the addition of trastuzumab to adjuvant chemotherapy, are highlighted. Comments from Soonmyung Paik, director of the project's Division of Pathology, regarding the findings are given.

The article discusses research being done on HER2 status and efficacy of adjuvant anthracyclines in early breast cancer. It references a study by A. Gennari et al published in the "Journal of the National Cancer Institute." The study revealed that although patients benefited from anthracyclines, their effect was moderate and were not constant through the different trials examined.

The article discusses a study of the impact of denosumab on bone mineral density among women with non-metastatic breast cancer taking adjuvant aromatase inhibitor therapy. Patients were divided based on duration of therapy. Results showed that density was preserved in larger portions of the denosumab group versus the placebo group.

The article discusses a study of a combination adjuvant therapy for patients with lymph node-positive breast cancer, which was presented at the 30th Annual San Antonio Breast Cancer Symposium in Texas. The therapy consists of bevacizumab and anthracycline. All patients enrolled in the study were assigned doxorubicin and cyclophosphamide followed by paclitaxel. Findings showed that myelosuppression was common in patients, whereas febrile neutropenia was uncommon.

The article reports on the approval by the U.S. Food and Drug Administration of trastuzumab as a single agent for the adjuvant treatment of HER2-positive and node-negative or node-positive breast cancer following anthracycline-based therapy. The decision was based on data from Herceptin Adjuvant trial , where patients who received the agent had a 46% reduction of cancer recurrence. Eric Winer of the Breast Oncology Center said the approval will not change clinical practice as clinicians have been using trastuzumab for node-negative patients.

The article reports on the discovery that the benefit of adjuvant anthracycline-based therapy appears to be restricted to women with HER2 positive breast cancers. A systematic review of published data from randomized, controlled adjuvant chemotherapy trials was performed by Dennis Slamon of the University of California at Los Angeles and his colleagues. They recommended that other approaches to the adjuvant treatment of breast cancer should be adopted.

This article reports that a study, getting under way this month in Canada, is expected to determine the impact of hospital design on staff efficiency and staff and patient satisfaction. Results will provide architects and developers with a basis for hospital renovations and design standards. Using palm pilote with a time and motion software package specifically designed for the study, observers will "shadow" a volunteer group of 10 nurses, several doctors and 60 breast cancer patients receiving adjuvant therapy over a one-week period at existing cancer facilities of Canada's Credit Valley Hospital in Mississauga, Ontario.